TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

NCT05132803 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study team decided not to move forward with the study.

Conditions

Recurrent Human Papillomavirus Type 16 Associated Cancer

Interventions

DRUG: HPV 16 TA-CIN

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins